Arecor Therapeutics plc (AREC.L)
LSE · GBp · Healthcare · Biotechnology
£82.50 (+0.00%) as of
Key statistics
- Market cap
- 37.37M
- P/E (TTM)
- 82.50
- Forward P/E
- -6.39
- EPS (TTM)
- 0.01
- Dividend yield
- 0.00%
- 52-week range
- 55.27 – 95.00
- Beta
- 0.08
- Revenue (TTM)
- 890k
- Profit margin
- 21.35%
- Analyst target
- £250.50
- Volume
- 60.00
About Arecor Therapeutics plc
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Little Chesterford, United Kingdom
- Employees
- 33
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.